Anxiety disorders are a prevalent and disabling condition. Because of high rates of treatment resistance, there is interest in new pharmacological treatment options such as second-generation antipsychotics. This systematic review evaluated the efficacy and tolerability of second-generation antipsychotics in the treatment of anxiety disorders. We found eleven randomised placebo-controlled trials, comparing quetiapine, olanzapine and risperidone with placebo and antidepressants. The vast majority of the available data was on quetiapine (> 3000 participants). Participants with generalised anxiety disorder responded significantly better to quetiapine than to placebo, measured as a reduction in the Hamilton Anxiety Scale (HAM-A). Participants treated with quetiapine were more likely to drop out due to adverse events, to gain weight, to suffer from sedation or to suffer from extrapyramidal side effects. The evidence on the other second-generation antipsychotics is currently too limited to draw any conclusions.
- Paradoxical effects of compulsive perseveration: sentence repetition causes semantic uncertainty
- Examining polygenic risk of cigarette use in the Detroit Neighborhood Health Study
- Population impact of depression either as a risk factor or consequence of type 2 diabetes in adults: A meta-analysis of longitudinal studies
- Sleep and borderline personality disorder: A review
- SNAP Costs Leveling Off, Almost Certain to Fall Next Year: Trends Reflect Flat Caseloads and Recent Benefit Cut
Category Specific RSS